Search filters

List of works by Saad Z Usmani

A Phase I, Open-Label Study of Siltuximab, an Anti–IL-6 Monoclonal Antibody, in Patients with B-cell Non-Hodgkin Lymphoma, Multiple Myeloma, or Castleman Disease ⬇️

scientific article published on May 9, 2013

A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma

scientific article published on 12 March 2019

Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma

scientific article

Autologous Stem Cell Transplantation as a Care Option in Waldenström's Macroglobulinemia ⬇️

scientific article published on February 1, 2011

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

scientific article published on 16 December 2019

Chimeric antigen receptor T cell therapy in multiple myeloma: promise and challenges

scientific article published on 07 August 2020

Chromosome 1q21 abnormalities in multiple myeloma

Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma (short title)

scientific article

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

scientific article published on 6 January 2016

Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma

scientific article published on 01 May 2019

Daratumumab plus lenalidomide and dexamethasone versus lenalidomide and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of POLLUX

scholarly article by Athanasios Dimopoulos et al published 20 September 2018 in Haematologica

Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma

scientific article

Daratumumab, lenalidomide, and dexamethasone in relapsed/refractory myeloma: a cytogenetic subgroup analysis of POLLUX

scientific article published on 03 November 2020

Greater treatment satisfaction in patients receiving daratumumab subcutaneous vs. intravenous for relapsed or refractory multiple myeloma: COLUMBA clinical trial results

scientific article published on 27 August 2020

HSP90 Inhibitors as Therapy for Multiple Myeloma ⬇️

scientific article published on April 28, 2011

IMWG consensus on risk stratification in multiple myeloma

scientific article published on 26 August 2013

Immune biomarkers of response to immunotherapy in patients with high-risk smoldering myeloma

Improvement in long-term outcomes with successive Total Therapy trials for multiple myeloma: are patients now being cured? ⬇️

scientific article published on June 18, 2012

International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma

scientific article published on August 2016

International Myeloma Working Group risk stratification model for smoldering multiple myeloma (SMM)

scientific article published on 16 October 2020

International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma

scientific article

International harmonization in performing and reporting minimal residual disease assessment in multiple myeloma trials

scientific article published on 11 August 2020

International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders

scientific article published on 01 June 2019

Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma

scientific article

Melphalan Continues to Rock the Myeloma World ⬇️

scientific article published on February 24, 2013

Metronomic therapy is an effective salvage treatment for heavily pre-treated relapsed/refractory multiple myeloma ⬇️

scientific article published on May 28, 2013

NAMPT/PBEF1 enzymatic activity is indispensable for myeloma cell growth and osteoclast activity ⬇️

scientific article published on February 19, 2013

Perspectives on the Risk-Stratified Treatment of Multiple Myeloma

Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3 ⬇️

scientific article published on May 31, 2011

Plasma cell leukemia: consensus statement on diagnostic requirements, response criteria and treatment recommendations by the International Myeloma Working Group

scientific article

Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis

scientific article published on 2 August 2016

Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols ⬇️

scientific article published on April 17, 2012

Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3 ⬇️

scientific article published on January 10, 2013

Risk factors for MDS and acute leukemia following total therapy 2 and 3 for multiple myeloma ⬇️

scientific article published on April 19, 2013

Rituximab and intravenous immunoglobulin (IVIG) for the management of acquired factor VIII inhibitor in multiple myeloma: case report and review of literature ⬇️

scientific article published on December 15, 2011

Role of 18F-FDG PET/CT in the diagnosis and management of multiple myeloma and other plasma cell disorders: a consensus statement by the International Myeloma Working Group

scientific article

Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease ⬇️

scientific article published on March 28, 2013

Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement

scientific article published on 20 January 2015

Second Primary Malignancies and Myeloma Therapy: Fad or Fact? ⬇️

scientific article published on September 1, 2012

Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance ⬇️

scientific article published on June 6, 2012

Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data

scientific article

Standard and novel imaging methods for multiple myeloma: correlates with prognostic laboratory variables including gene expression profiling data ⬇️

scientific article published on June 24, 2012

Subcutaneous delivery of daratumumab in relapsed or refractory multiple myeloma

scientific article published on 03 July 2019

The 2020 BMT CTN Myeloma Intergroup Workshop on Immune Profiling and Minimal Residual Disease Testing in Multiple Myeloma

The anti-myeloma activity of a novel purine scaffold HSP90 inhibitor PU-H71 is via inhibition of both HSP90A and HSP90B1 ⬇️

scientific article published on October 26, 2010

Treatment outcomes of triple class refractory multiple myeloma: a benchmark for new therapies

scientific article published in 2021

Waldenström's Macroglobulinemia Associated with Serum Amyloid A Protein Amyloidosis: Pitfalls in Diagnosis and Successful Treatment with Melphalan-Based Autologous Stem Cell Transplant ⬇️

scientific article published on May 9, 2013

Paulina is supported by:

About Paulina

Help